BR112014027571A2 - métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas - Google Patents

métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas

Info

Publication number
BR112014027571A2
BR112014027571A2 BR112014027571A BR112014027571A BR112014027571A2 BR 112014027571 A2 BR112014027571 A2 BR 112014027571A2 BR 112014027571 A BR112014027571 A BR 112014027571A BR 112014027571 A BR112014027571 A BR 112014027571A BR 112014027571 A2 BR112014027571 A2 BR 112014027571A2
Authority
BR
Brazil
Prior art keywords
methods
patient
diabetic retinopathy
treating
treatment
Prior art date
Application number
BR112014027571A
Other languages
English (en)
Other versions
BR112014027571B1 (pt
Inventor
Olof Bavik Claes
Kubota Ryo
Hayes Henry Susan
A Kuksa Vladimir
Original Assignee
Acucela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acucela Inc filed Critical Acucela Inc
Publication of BR112014027571A2 publication Critical patent/BR112014027571A2/pt
Publication of BR112014027571B1 publication Critical patent/BR112014027571B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Abstract

resumo “métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas” métodos são fornecidos aqui para o tratamento de doenças ou condições oftálmicas, tal como uma doença ou desordem oftálmica associada com diabetes em um paciente. também aqui são proporcionados métodos de tratamento de retinopatia da prematuridade em um paciente. além disso, proporcionam-se aqui métodos para tratar a degeneração macular relacionada com a idade num paciente. os métodos compreendem a administração dos compostos aqui descritos a um paciente em necessidade do mesmo que inibem ou retarda um ou mais sinais ou sintomas de tais condições.
BR112014027571-8A 2012-05-04 2013-05-03 Uso de um composto BR112014027571B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261643058P 2012-05-04 2012-05-04
US201261643051P 2012-05-04 2012-05-04
US201261643178P 2012-05-04 2012-05-04
US61/643,051 2012-05-04
US61/643,058 2012-05-04
US61/643,178 2012-05-04
US201361781907P 2013-03-14 2013-03-14
US61/781,907 2013-03-14
PCT/US2013/039562 WO2013166449A2 (en) 2012-05-04 2013-05-03 Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

Publications (2)

Publication Number Publication Date
BR112014027571A2 true BR112014027571A2 (pt) 2017-07-18
BR112014027571B1 BR112014027571B1 (pt) 2021-08-31

Family

ID=49515046

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027571-8A BR112014027571B1 (pt) 2012-05-04 2013-05-03 Uso de um composto

Country Status (18)

Country Link
US (3) US9957224B2 (pt)
EP (2) EP2844636B1 (pt)
JP (5) JP2015518491A (pt)
KR (1) KR20150013240A (pt)
CN (3) CN107865830A (pt)
AU (1) AU2013256029A1 (pt)
BR (1) BR112014027571B1 (pt)
CA (1) CA2872433C (pt)
EA (1) EA201492031A1 (pt)
ES (1) ES2792923T3 (pt)
HK (2) HK1203478A1 (pt)
IL (1) IL235446A0 (pt)
MX (2) MX2014013341A (pt)
PH (1) PH12014502449A1 (pt)
SG (1) SG11201407162SA (pt)
TW (1) TW201406707A (pt)
WO (1) WO2013166449A2 (pt)
ZA (1) ZA201408592B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5913805B2 (ja) 2007-10-05 2016-04-27 アキュセラ， インコーポレイテッド 疾患治療用アルコキシ化合物
JP2015505536A (ja) 2012-01-20 2015-02-23 アクセラ インク． 疾患の処置のための置換された複素環化合物
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
AU2014248878A1 (en) * 2013-03-12 2015-09-24 Acucela Inc. Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
AU2014228568B2 (en) 2013-03-14 2018-06-14 Amo Development, Llc Laser capsulovitreotomy
AU2015243261B2 (en) * 2014-04-10 2020-06-25 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
US10792374B2 (en) 2015-10-09 2020-10-06 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
CA3054735A1 (en) * 2017-02-27 2018-08-30 Case Western Reserve University Visual cycle modulators
EP3733050A4 (en) * 2017-12-28 2021-08-11 Nikon Corporation Image processing method, image processing program, image processing device, image display device and image display method
MX2018008165A (es) * 2018-06-29 2019-12-30 Centro De Retina Medica Y Quirurgica S C Sistema portátil para la identificación de casos potenciales de edema macular diabético mediante procesamiento de imagen e inteligencia artificial.
JP2021529068A (ja) 2018-07-07 2021-10-28 アキュセラ インコーポレイテッド 網膜低酸素症を防止するためのデバイス
KR20210032529A (ko) 2018-07-30 2021-03-24 어큐셀라 인코포레이티드 근시 진행을 감소시키기 위한 전자 콘택트 렌즈의 광학 설계
JP2022512706A (ja) * 2018-10-16 2022-02-07 エフ．ホフマン－ラ ロシュ アーゲー 眼科におけるＡｋｔ阻害剤の使用
WO2020081941A1 (en) * 2018-10-19 2020-04-23 Medicinova, Inc. Methods of treating ophthalmic disease/disorder or injury with ibudilast
JPWO2020240867A1 (pt) * 2019-05-31 2020-12-03
EP4003250A4 (en) 2019-07-31 2023-08-23 Acucela Inc. DEVICE FOR PROJECTING IMAGES ONTO THE RETINA
WO2021056018A1 (en) 2019-09-16 2021-03-25 Acucela Inc. Assembly process for an electronic soft contact lens designed to inhibit progression of myopia
US11777340B2 (en) 2020-02-21 2023-10-03 Acucela Inc. Charging case for electronic contact lens
CN111617313B (zh) * 2020-04-29 2022-09-06 天津医科大学眼科医院 一种眼用线性凝胶在作为临床孔源性视网膜脱离药物方面中的应用
CA3177695A1 (en) 2020-05-13 2021-11-18 Ryo Kubota Electro-switchable spectacles for myopia treatment
CN115698832A (zh) 2020-06-08 2023-02-03 奥克塞拉有限公司 用于治疗散光的非对称投影透镜
CA3174148A1 (en) 2020-06-08 2021-12-16 Acucela Inc. Projection of defocused images on the peripheral retina to treat refractive error
JP2023528307A (ja) 2020-06-08 2023-07-04 アキュセラ インコーポレイテッド 周辺脱焦点化を使用して進行性屈折異常を治療するための貼付式デバイス
US11281022B2 (en) * 2020-06-10 2022-03-22 Acucela Inc. Apparatus and methods for the treatment of refractive error using active stimulation
US11209672B1 (en) 2021-04-06 2021-12-28 Acucela Inc. Supporting pillars for encapsulating a flexible PCB within a soft hydrogel contact lens
US11366341B1 (en) 2021-05-04 2022-06-21 Acucela Inc. Electronic case for electronic spectacles
WO2022245697A1 (en) * 2021-05-16 2022-11-24 Metanoia Bio Inc. Methods and compositions for treating ocular neovascular disease
WO2022255332A1 (ja) * 2021-06-03 2022-12-08 国立大学法人大阪大学 未熟児網膜症スクリーニング方法、スクリーニング装置及び学習済モデル

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
RS35404A (en) * 2001-11-09 2006-10-27 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
CN1964706A (zh) * 2004-03-17 2007-05-16 拉斯·M·拉森 通过抑制视觉周期预防视网膜病
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
KR101368248B1 (ko) 2007-04-20 2014-03-14 어큐셀라 인코포레이티드 안과 질환 및 장애 치료용 스티레닐 유도체 화합물
KR101196680B1 (ko) * 2007-06-29 2012-11-06 어큐셀라 인코포레이티드 안과 질환 및 장애 치료용 알키닐 페닐 유도체 화합물
JP5913805B2 (ja) * 2007-10-05 2016-04-27 アキュセラ， インコーポレイテッド 疾患治療用アルコキシ化合物
EP2111223A4 (en) 2007-11-01 2012-08-15 Acucela Inc AMIN DERIVATIVE COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
GB2463151A (en) 2008-09-05 2010-03-10 Acucela Inc Amine derivative compounds for treating ophthalmic diseases and disorders
AU2009308483C1 (en) * 2008-10-22 2014-01-23 Acucela, Inc. Compounds for treating ophthalmic diseases and disorders
JP5860398B2 (ja) * 2009-07-02 2016-02-16 アキュセラ インコーポレイテッド 視覚サイクルモジュレーターの薬理
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法

Also Published As

Publication number Publication date
WO2013166449A3 (en) 2014-01-30
MX2020001835A (es) 2021-09-09
CN104411678A (zh) 2015-03-11
CA2872433A1 (en) 2013-11-07
US10730825B2 (en) 2020-08-04
JP2020023535A (ja) 2020-02-13
HK1203478A1 (en) 2015-10-30
US20140039048A1 (en) 2014-02-06
JP2021075576A (ja) 2021-05-20
CN116850163A (zh) 2023-10-10
EP2844636A4 (en) 2016-03-09
HK1246646A1 (zh) 2018-09-14
WO2013166449A2 (en) 2013-11-07
US20180346407A1 (en) 2018-12-06
PH12014502449A1 (en) 2015-01-12
US20210171435A1 (en) 2021-06-10
KR20150013240A (ko) 2015-02-04
MX2014013341A (es) 2015-06-02
EP2844636A2 (en) 2015-03-11
JP2018024702A (ja) 2018-02-15
TW201406707A (zh) 2014-02-16
EP3741742A1 (en) 2020-11-25
IL235446A0 (en) 2014-12-31
CA2872433C (en) 2022-06-28
BR112014027571B1 (pt) 2021-08-31
ES2792923T3 (es) 2020-11-12
ZA201408592B (en) 2017-09-27
JP2015518491A (ja) 2015-07-02
AU2013256029A1 (en) 2014-12-04
EP2844636B1 (en) 2020-04-22
SG11201407162SA (en) 2014-11-27
CN107865830A (zh) 2018-04-03
JP2023059991A (ja) 2023-04-27
US11795136B2 (en) 2023-10-24
US9957224B2 (en) 2018-05-01
EA201492031A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
PH12015501352A1 (en) Compositions and methods that utilize a peptide tag that binds to hyaluronan
BR112015011158A2 (pt) triazolopirazina
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
BR112015010360A8 (pt) antagonistas de il-6 e utilização dos mesmos.
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112013027119A2 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112014006684A2 (pt) análogos de glucagon
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112014031788A2 (pt) composições e métodos para o tratamento de diabetes
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
BR112017012588A2 (pt) compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta)
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112015023669A2 (pt) novos derivados de ciclosporina e suas utilizações
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112015019919A2 (pt) compostos bicíclicos
BR112015007360A8 (pt) Composição farmacêutica, e, método para a preparação de uma droga de combinação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/05/2013, OBSERVADAS AS CONDICOES LEGAIS.